In short
Tirzepatide is a dual GIP and GLP-1 receptor agonist peptide, and tirzepatide side effects are documented in randomised trials with up to 13,165 analysed participants. The dominant finding is gastrointestinal: nausea, diarrhoea and vomiting, mostly mild to moderate and concentrated in the dose escalation period.
- Discontinuation for adverse events ran 4.3 to 7.1 % on tirzepatide against 2.6 % on placebo in SURMOUNT-1 (2022, n = 2,539)
- Serious adverse events were not increased in a 2026 meta-analysis of 21 placebo controlled trials
- Pancreatitis was rare; gallbladder events were more frequent than with control
- This is a literature summary, not guidance for human use; mechanism and efficacy are in the tirzepatide research overview
What are the most common tirzepatide side effects?
The most common side effects of tirzepatide in trials are gastrointestinal: nausea, diarrhoea, vomiting and decreased appetite. SURMOUNT-1 described them as mostly mild to moderate and occurring primarily during dose escalation (Jastreboff 2022, n = 2,539, PubMed 35658024).
In SURPASS-1, a 40 week placebo controlled trial in type 2 diabetes, nausea affected 12 to 18 % of participants on tirzepatide against 6 % on placebo (Rosenstock 2021, n = 478, PubMed 34186022). A meta-analysis of ten trials found gastrointestinal events rising with dose, from 39 % in the lowest dose arm to 49 % in the highest dose arm (Mishra 2023, n = 6,836, PubMed 36789109).
In SURPASS-2, a head to head trial against semaglutide in type 2 diabetes, nausea was reported by 17 to 22 % on tirzepatide and 18 % on the comparator (Frías 2021, n = 1,879, PubMed 34170647).
Tirzepatide adverse events by trial
Tirzepatide trials show more gastrointestinal events than placebo or insulin, less hypoglycaemia than insulin and discontinuation rates of up to 10 %. Figures are as stated in each abstract.
| Trial (first author, year) | n, duration, population | Comparator | Gastrointestinal events | Other findings |
|---|---|---|---|---|
| SURPASS-2 (Frías 2021) | 1,879, 40 weeks, type 2 diabetes | semaglutide | nausea 17 to 22 % vs 18 % | serious events 5 to 7 % vs 3 % |
| SURPASS-3 (Ludvik 2021) | 1,437, 52 weeks, type 2 diabetes | basal insulin | nausea 12 to 24 % vs 2 % | hypoglycaemia 1 to 2 % vs 7 % |
| SURPASS-4 (Del Prato 2021) | 1,995, up to 104 weeks, high cardiovascular risk | basal insulin | nausea 12 to 23 % vs 2 % | hypoglycaemia 6 to 9 % vs 19 % |
| SURMOUNT-1 (Jastreboff 2022) | 2,539, 72 weeks, obesity | placebo | mostly mild to moderate | discontinuation 4.3 to 7.1 % vs 2.6 % |
| SURMOUNT-2 (Garvey 2023) | 938, 72 weeks, obesity with diabetes | placebo | mostly mild to moderate | discontinuation under 5 % |
| SURPASS-CVOT (Nicholls 2025) | 13,165, diabetes with cardiovascular disease | GLP-1 agonist | more than comparator | overall incidence similar |
Is tirzepatide safe? What pooled data show
Pooled trial data answer the serious event part of whether tirzepatide is safe: a 2026 meta-analysis of 21 placebo controlled trials found no difference in serious adverse events, odds ratio 0.98 (95 % CI 0.82 to 1.17), with moderate certainty (Sillassen 2026, n = 8,043, PubMed 41896878).
Mortality data were sparse and rated very low certainty. In Mishra 2023, stopping for adverse events peaked at 10 % in the highest dose arm. Class level context is in are peptides safe.
Pancreatitis, gallbladder and hypoglycaemia
Acute pancreatitis was rare in tirzepatide trials and showed no dose response, while gallbladder events were more frequent than in control groups. A 2026 meta-analysis of 19 trials recorded acute pancreatitis in 0.22 % of participants, with no significant difference between dose arms (Benny 2026, n = 15,471, PubMed 41927408).
Nine trials gave a risk ratio of 1.97 (95 % CI 1.14 to 3.42) for gallbladder or biliary disease against placebo or basal insulin (Zeng 2023, n = 9,871, PubMed 37908750). A later analysis of 12 trials reported 1.52 for gallbladder or biliary disease and 1.67 for gallstones, without dose response (Gong 2025, n = 12,351, PubMed 39569606).
Hypoglycaemia depends on comparator and background therapy. In SURPASS-4, among participants not taking sulfonylureas, it occurred in 1 to 3 % on tirzepatide against 16 % on basal insulin (Del Prato 2021, n = 1,995).
Tirzepatide injection site reactions and long term side effects
Injection site reactions with tirzepatide are documented mainly through post marketing reports. A 2026 analysis of 123,145 US FDA adverse event reports named medication errors and injection site reactions as the strongest signals; across all events with onset data, the median onset was 13 days (Guo 2026, PubMed 42443144).
Reports do not measure incidence. For tirzepatide long term side effects, most pooled analyses cover 26 to 72 weeks. SURPASS-4 ran up to 104 weeks without excess cardiovascular events (Del Prato 2021, hazard ratio 0.74), and SURPASS-CVOT found tirzepatide noninferior on cardiovascular outcomes (Nicholls 2025, n = 13,165, hazard ratio 0.92).
Tirzepatide and cancer: rodents, trials and open questions
The cancer question around tirzepatide starts in rodents: rat studies of GLP-1 receptor agonists show more thyroid C-cell tumours, while human trial data so far show no increase in cancer. Both statements have limits.
In rats, GLP-1 receptor agonists caused calcitonin release and C-cell hyperplasia; primate C-cells expressed little of the receptor, and 20 months of exposure to one agonist caused no hyperplasia in monkeys (Bjerre Knudsen 2010, PubMed 20203154). A 2026 weight of evidence review of seven approved agonists, tirzepatide included, concluded that the rat tumours arise through a mechanism not relevant to humans (Roach 2026, PubMed 42800499). The boxed warning for medullary thyroid carcinoma remains.
In humans, 13 trials gave a risk ratio for any cancer of 0.78 (95 % CI 0.53 to 1.16) over 26 to 72 weeks, with no papillary thyroid carcinoma, although calcitonin rose more in higher dose arms (Kamrul-Hasan 2025, n = 13,761, PubMed 39814031). For the class, trials show thyroid cancer as rare, while pharmacovigilance shows a reporting signal (Espinosa De Ycaza 2024, PubMed 38343381). Unknown: effects beyond the trial horizons, and any small rise in rare medullary carcinoma.
Where to buy tirzepatide for research with a published certificate
Molequa® supplies tirzepatide exclusively as laboratory research material, and the certificate of analysis from the independent laboratory Analyton Labs (analyton.com) is published before purchase.
For tirzepatide for research (62.90 € per vial labelled 5 mg on 23 October 2026), report AN-2026-00014 for batch MQ-TIRZEPATIDE-202609, issued on 1 August 2026, records identity by LC-HRMS at 0.8 ppm mass deviation, RP-HPLC purity of 99.25 % (C18, 214 nm), peptide content of 94.80 % w/w and endotoxins below 0.05 EU/mg; a screen for fentanyl analogues and other incretin peptides found none above 0.05 % of area. HPLC purity is the share of the main peak, not peptide content. See the certificate for batch MQ-TIRZEPATIDE-202609 and how to verify a peptide supplier.
Frequently asked questions
What are the most common tirzepatide side effects? Gastrointestinal events such as nausea, diarrhoea and vomiting, mostly mild to moderate and early.
Is tirzepatide safe according to trial data? A 2026 meta-analysis of 21 placebo controlled trials found no difference in serious adverse events. Most pooled analyses cover 26 to 72 weeks of exposure.
Does tirzepatide cause cancer? Rat studies show thyroid C-cell tumours. A 2025 meta-analysis of 13 trials found no increase in overall or specific cancer over 26 to 72 weeks.
What are the long term side effects of tirzepatide? The longest controlled data, SURPASS-4 up to 104 weeks and SURPASS-CVOT, found no excess cardiovascular events. Most other data cover 26 to 72 weeks.
Are injection site reactions reported with tirzepatide? Yes. In US FDA adverse event reports they are among the strongest signals, but such reports do not measure incidence.
Legal notice
All products under the Molequa® brand are intended exclusively for scientific laboratory research (Research Use Only). They are not medicines, dietary supplements, cosmetic products or food, and they are not intended for human or animal consumption or for application to human or animal skin. Scientific data cited in this article come from published literature and describe research conducted with the relevant substances. They are not a claim about the products sold, nor a recommendation for use.
